Nalaganje...
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast gr...
Shranjeno v:
| izdano v: | J Exp Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223586/ https://ncbi.nlm.nih.gov/pubmed/28069043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0478-9 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|